Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | CCKBR | P32239 | 11/20 | 0.38 |
| ▸ | AMY2A | P04746 | 8/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31414641 | 0.87 | NMBR (0.46) | ACECTSSCTSLCTSBCTSK | |
| SCHEMBL34461946 | 0.86 | REN (0.39) | CCKBRCCKAROPRD1 | |
| SCHEMBL34461945 | 0.86 | REN (0.40) | CCKBRCCKAROPRD1 | |
| SCHEMBL30343346 | 0.85 | PSEN1 (0.36) | OPRD1 | |
| SCHEMBL30437059 | 0.84 | REN (0.39) | CCKBRCCKAROPRD1 | |
| SCHEMBL30524338 | 0.84 | PSEN1 (0.38) | OPRD1 | |
| SCHEMBL30665993 | 0.83 | NMBR (0.44) | CTSSCTSLCTSBCTSKSIRT2 | |
| SCHEMBL30250211 | 0.83 | OPRD1 (0.36) | CCKBRCCKAROPRD1 | |
| SCHEMBL31094168 | 0.83 | REN (0.38) | ACECTSSCTSLCTSBCTSK | |
| SCHEMBL30065645 | 0.83 | SIRT2 (0.40) | ACESIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | BIOCON LIMITED (IN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067694-A1 | SYNTHESIS OF TEDUGLUTIDE | DNPEP, GCLC, PTMS | ACE 533/4885CTSS 196/4885CTSL 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.